European Journal of Cardiovascular Medicine

Allergic rhinitis is the most common atopic disorder seen in the outpatient clinic. Montelukast, is a novel medication, is an antagonist to the leukotriene receptor. The aim of this work was to identify the improvement in the severity of symptoms of child with AR treated with Montelukast. A cross-sectional study was conducted among fifty-patients with a chronic cough and (sneezing, nasal congestion, rhinorrhea, and postnasal drip) at least eight weeks using Montelukast between the periods of January 2019 to March 2019. By using the symptom severity score for AR, that calculated. Data including (age, gender, associated disease, exacerbation factors, and classical therapy). The dose of 10-mg Montelukast once daily was prescribed. On follow-up, after four-weeks, compliance was ensured and then the symptom severity score was recorded again. Most of patients aged above 40 years. Males to females ratio was 1:1.5. Most of patients (40, 80%) lived in urban regions. There was a reduction of the symptoms associated with RA after treatment with Montelukast. Exacerbation factors was as following, dust was found in 80%, food 40%, exercise 64%, psychological 50%, and smoking 48%. SSS was declined after therapy significantly (P=0.05). Patients using showed improvement of symptoms, pain was relieved from 82%, exhaustion 80%, vomiting 92%, sleep disturbance in 80%, affecting daily life in 88%, and syncope 96%. In conclusion, the common symptoms of AR are improvement in response to Montelukast. The improvement in the symptom severity score was maximum in sneezing-nasal congestion- rhinorrhea and least in postnasal drip